Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Recommendations for treatment discontinuation in CML

Francois-Xavier Mahon • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, outlines the latest recommendations for tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML), explaining how to increase the number of candidates for treatment-free remission (TFR). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francois-Xavier Mahon

0:54
Design & aims of the EURO-SKI trial in CML
Francois-Xavier Mahon • 22 Oct 2022
1:24
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
Francois-Xavier Mahon • 22 Oct 2022
1:05
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
Francois-Xavier Mahon • 26 Nov 2021
4:57
EURO-SKI: 3-year follow-up data of TKI cessation in CML
Francois-Xavier Mahon • 26 Nov 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals